EA202191509A1 - Способы лечения фолликулярной лимфомы - Google Patents

Способы лечения фолликулярной лимфомы

Info

Publication number
EA202191509A1
EA202191509A1 EA202191509A EA202191509A EA202191509A1 EA 202191509 A1 EA202191509 A1 EA 202191509A1 EA 202191509 A EA202191509 A EA 202191509A EA 202191509 A EA202191509 A EA 202191509A EA 202191509 A1 EA202191509 A1 EA 202191509A1
Authority
EA
Eurasian Patent Office
Prior art keywords
follicular lymphoma
methods
lymphoma treatment
treatment
predict
Prior art date
Application number
EA202191509A
Other languages
English (en)
Russian (ru)
Inventor
Срирам Баласубраманиан
Original Assignee
Янссен Байотек, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Янссен Байотек, Инк. filed Critical Янссен Байотек, Инк.
Publication of EA202191509A1 publication Critical patent/EA202191509A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
EA202191509A 2018-11-30 2019-11-26 Способы лечения фолликулярной лимфомы EA202191509A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862773678P 2018-11-30 2018-11-30
PCT/US2019/063234 WO2020112761A1 (en) 2018-11-30 2019-11-26 Methods of treating follicular lymphoma

Publications (1)

Publication Number Publication Date
EA202191509A1 true EA202191509A1 (ru) 2021-10-26

Family

ID=68966021

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202191509A EA202191509A1 (ru) 2018-11-30 2019-11-26 Способы лечения фолликулярной лимфомы

Country Status (16)

Country Link
US (1) US20200171034A1 (https=)
EP (1) EP3886992A1 (https=)
JP (1) JP2022513666A (https=)
KR (1) KR20210097160A (https=)
CN (1) CN113164782A (https=)
AU (1) AU2019388899A1 (https=)
BR (1) BR112021009978A2 (https=)
CA (1) CA3120960A1 (https=)
EA (1) EA202191509A1 (https=)
IL (1) IL283365A (https=)
JO (1) JOP20210126A1 (https=)
MA (1) MA54292A (https=)
MX (1) MX2021006368A (https=)
PH (1) PH12021551140A1 (https=)
SG (1) SG11202105309YA (https=)
WO (1) WO2020112761A1 (https=)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2983670A4 (en) * 2013-04-08 2017-03-08 Pharmacyclics LLC Ibrutinib combination therapy
CA2914284A1 (en) * 2013-05-30 2014-12-04 Infinity Pharmaceuticals, Inc. Treatment of cancers using pi3 kinase isoform modulators
US20160032404A1 (en) * 2014-08-01 2016-02-04 Pharmacyclics Llc Biomarkers for predicting response of dlbcl to treatment with a btk inhibitor
CA2980393A1 (en) * 2015-03-18 2016-09-22 Memorial Sloan Kettering Cancer Center Methods for diagnosing and treating follicular lymphoma
HK1250925A1 (zh) * 2015-04-06 2019-01-18 Janssen Pharmaceutica, N.V. 包含依鲁替尼的组合物
WO2017087947A2 (en) * 2015-11-19 2017-05-26 Pharmacyclics Llc Method of treatment of follicular lymphoma with a btk inhibitor
PH12021551936A1 (en) * 2019-02-15 2022-05-23 Janssen Biotech Inc Combination therapy for treatment of b-cell malignancies

Also Published As

Publication number Publication date
CN113164782A (zh) 2021-07-23
JOP20210126A1 (ar) 2019-11-26
SG11202105309YA (en) 2021-06-29
KR20210097160A (ko) 2021-08-06
EP3886992A1 (en) 2021-10-06
US20200171034A1 (en) 2020-06-04
JP2022513666A (ja) 2022-02-09
BR112021009978A2 (pt) 2021-08-17
WO2020112761A1 (en) 2020-06-04
MA54292A (fr) 2021-10-06
PH12021551140A1 (en) 2021-10-25
AU2019388899A1 (en) 2021-06-10
IL283365A (en) 2021-07-29
MX2021006368A (es) 2021-10-13
CA3120960A1 (en) 2020-06-04

Similar Documents

Publication Publication Date Title
PH12019501575A1 (en) ISOFORM-SPECIFIC, CONTEXT-PERMISSIVE TGFá1 INHIBITORS AND USE THEREOF
MX2021005394A (es) Co-formulaciones de anticuerpos anti-gen de activacion de linfocitos 3 (anti-lag3) y anticuerpos anti-muerte programada-1 (anti-pd-1).
PH12020551683A1 (en) Biomarkers for graft-versus-host disease
BR112018001853A2 (pt) métodos para tratamento de um distúrbio e para melhoria do tratamento de um distúrbio
EA201990296A1 (ru) Антитела против siglec-7 для лечения рака
EA201791884A1 (ru) Химерные антигенные рецепторы против dll3 и способы применения
EA201792545A1 (ru) Способы и наборы для лечения депрессии
MY196631A (en) Antibody Agents Specific for Human Cd19 and uses Thereof
EP4603508A3 (en) Anti-frizzled antibodies and methods of use
SG10201901076WA (en) Methods of treating alzheimer's disease
EA202191067A1 (ru) Композиции и способы для лечения дефицита альфа-1-антитрипсина
MA38827A1 (fr) Combinaison d'un inhibiteur de mek et d'un inhibiteur d'erk pour l'utilisation dans le traitement de maladies hyperprolifératives
MY196448A (en) Anti-Htra1 Antibodies and Methods of use Thereof
EA201692472A1 (ru) Соединения для лечения рака мозга
MX2020006297A (es) Variantes de cd19.
CY1124123T1 (el) Φαρμακευτικοι συνδυασμοι για θεραπεια καρκινου
EA201891664A1 (ru) Составы/композиции, содержащие ингибитор btk
MX2019001958A (es) Metodos para tratar la enfermedad de crohn con un anticuerpo anti-nkg2d.
EA202092156A1 (ru) Модифицированные олигонуклеотиды и способы применения в лечении таупатий
JOP20210143A1 (ar) تركيبات وطرق لعلاج ومنع التصلب الجانبي الضموري
EA202091881A1 (ru) Соединения для лечения боли
UY38352A (es) Inhibidores de integrina alfavbeta6
MX2017013047A (es) Tratamiento de dolor.
BR112019024875A2 (pt) Métodos para o tratamento da ileíte do reservatório crônica
IL283564A (en) Radiation-treated fibers, methods of treating and applications for use